Current Report No. 17/2025 – Execution of an Agreement by a Subsidiary with the General Contractor of the Investment Project,

Date: 3 October 2025, 17:07

Legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council (MAR) – inside information

The Management Board of Celon Pharma S.A. (the “Company”, the “Issuer”) announces that on 3 October 2025 the Issuer’s subsidiary – Celon Pharma Slovakia s.r.o. (“Celon Pharma Slovakia”, the “Investor”) – concluded an agreement with Polonez Plus sp. z o.o. (the “Contractor”).

The subject of the agreement is the performance by the Contractor of the function of general contractor for the investment project consisting in the construction of the Celon Pharma Slovakia manufacturing facility located in the business park in Žilina, Slovakia (the “Agreement”). The Investor has obtained rights to use the property for construction purposes and to carry out the works covered by the Agreement from CTPark Žilina Airport spol. s r.o., the owner of the property.

The conclusion of the Agreement constitutes a significant stage in the implementation of the Issuer Group’s development strategy, aimed at the development of the Company’s product portfolio, including the provision of adequate manufacturing capacity for modern therapies based on GLP-1 analogues, as well as the geographical diversification of production infrastructure.

Under the Agreement, the Contractor will be responsible for procuring and delivering equipment and materials for the Investor and performing preparatory works in accordance with the execution design. Following the Investor’s receipt of a final building permit, the Contractor will also be responsible for carrying out the construction works and installing the delivered equipment and materials.

Completion of the works covered by the building permit is expected within 12 months from the commencement of construction works.

The total net value of the Agreement has been set in euros and amounts to the equivalent of PLN 63.3 million, calculated on the basis of the average EUR/PLN exchange rate announced by the National Bank of Poland on the date of signing the Agreement.

The Agreement provides for contractual penalties in favour of Celon Pharma Slovakia, payable, inter alia, in the event of delays in performance or in the removal of defects. It also provides for a contractual penalty of 5% of the net Agreement value in the event of termination of the Agreement by either party. The total amount of contractual penalties under the Agreement, both for the Investor and the Contractor, may not exceed 10% of the net Agreement value. The parties retain the right to pursue damages under general principles in the event of losses exceeding the contractual penalty limit.

The Issuer considers this information significant due to its importance for the development of the operational and production activities of the Celon Pharma Group.